On January 29th, 2019, as a rapidly-growing IVD company specialized in pathological diagnostics with a focus on immunohistochemical (IHC), Talent announced the availability of 102 primary antibodies marked NMPA. Together with 257 primary antibodies approved 6 months before, Talent already had a complete product list of 359 reagents which could meet nearly all needs from pathology laboratory.
Part of primary antibodies approved this batch:
AR，Arginase-1，BRCA1，HBsAg，HBcAg，CDK4，CK5，HHV-8，HPV16，MMP-9，Myogenin，Melanoma，H3K27M，H3K27Me3，PD-1，Bob.1，CD146，CD44v6，LMP-1，MUC-4，SOX-10， MGMT，INI-1，Stathmin，STAT6，PHH3，SATB2，Skeletal Myosin，Survivin，Uroplakin Ⅲ，Brdu，CD45RA，ERG， Factor XⅢ A，MHA，T-PIT，PIT-1，CD44(v6)，Thymidylate Synthase，Cathepsin D，DPC4，HSP27，SSTR 2，Fibrinogen，Perforin，Cadherin 17，MiTF，Uroplakin Ⅱ，Surfactant Protein A，PSCA，TG，DYS1，DYS2，NKX2.2，Brachyury，Caveolin-1，CK 10＆13），Osteopontin，VEGFR2，MDR-1，NKX3.1，CD42b， HGAL，MASH1，LIN28， TRIM29，FH，Digoxin，Cytomegalovirus，SF-1，CD33，MYB，FOXL2，SOX-9，SMARCA4 ，BCL-10，CLaudin 7，HSP70），H3.3G34W，NUT，CLaudin 18.2，H3.3G34R，Helicobacter phlori，H3.3G34V，Fibrinogen-FITC，IgA-FITC，IgG-FITC，IgM-FITC，C1q-FITC，C3c-FITC，C4c-FITC，NTRK，INSM1